Blog

Company News

Industry Trends

Laws Regulations

All Categories >

30

2024-04

Hycells New Product | Anti-Payload—MMAE/MMAF/DXD Antibody

Antibody–drug conjugates (ADCs) are an emerging class of targeted therapies for cancer treatment, designed to deliver cytotoxic small-molecule payloads directly to and selectively kill tumor cells. Essentially a form of targeted chemotherapy, ADCs have now advanced to the third generation, with substantial improvements in both safety and efficacy. Technological innovations in this field have primarily focused on the payload, the linker, and the conjugation chemistry, while the engineering and optimization of the payload remain a central focus for enhancing ADC performance.

2024-04-30

He Yousheng

25

2024-04

Welcome to the leaders of Daxing District, Beijing, for their visit to Hycells to conduct research and provide guidance!

On April 23, 2024, a delegation of leaders headed by Duan Xiaoyan, Deputy Secretary of the Party Working Committee and Director of the Xingfeng Subdistrict Office of Beijing Municipality, paid a visit to Hycells for inspection and guidance. Accompanying the delegation were Cao Danhua, Head of the Comprehensive Division of the Research Office of the District Party Committee; Shi Qian, Head of the Document Management Division of the District Government Office; Liu Yongxin, Member of the Party Leadership Group and Deputy Director of the Emerging Industries Promotion Service Center; and Sun Jingliang, Deputy Director of the Investment Promotion Department of the Daxing District Investment Promotion Center. Zhou Bin, General Manager of Hycells, and Yu Maoqian, Deputy General Manager, extended a warm welcome to Director Duan and her delegation.

2024-04-25

He Yousheng

25

2024-04

Hycells New Product | Our In-House Anti-FMC63 Antibody Is Now Available!

In the research, development, and manufacturing of CAR-T products, the CAR expression rate is a critical research parameter and performance indicator that is integral throughout preclinical studies, process development, and product quality control, and it also serves as an excellent companion diagnostic marker in subsequent clinical trials.

2024-04-25

He Yousheng

12

2024-04

Hycells New Product | Tackling the Challenges of Cryopreserving “Off-the-Shelf” NK and γδ T Cells

Cell cryopreservation media serve as the liquid environment during cryopreservation, providing nutrients and protective effects to cells. They lower the freezing point, increase the permeability of cell membranes to water, and facilitate the efflux of intracellular water prior to freezing, thereby preventing or minimizing ice-crystal-induced damage. This allows cells to be temporarily suspended from active growth while preserving their cellular characteristics, so that they can be directly revived when needed to regain viability. Traditionally, cell cryopreservation media are prepared by mixing culture medium, serum, and DMSO in specific ratios; however, due to the complex composition of serum and significant batch-to-batch variability, their application is limited, and they require a stepwise cooling protocol for cryopreservation, which is time-consuming and labor-intensive.

2024-04-12

He Yousheng

12

2024-04

Hycells New Product | Anti-Payload-DXD Antibody

Antibody–drug conjugates (ADCs) are a class of promising biologic therapeutics designed to selectively deliver highly cytotoxic payloads to tumor cells while sparing normal tissues. They can be regarded as prodrugs that remain stable in the bloodstream, minimizing drug release during circulation and enabling efficient conversion to the active form at the tumor site. Designing the optimal tripartite combination of monoclonal antibody (mAb), linker, and payload requires careful monitoring and understanding of the physicochemical properties of these three components in both the systemic circulation and the tumor microenvironment. In particular, the linker plays a critical role in determining the potency and safety profile of the ADC; therefore, in vivo assessment of “drug–linker stability” is essential for guiding linker selection, which is typically achieved through the determination of pharmacokinetic (PK) parameters.

2024-04-12

He Yousheng

06

2024-03

Good News | Hycells Biotechnology Awarded Shanghai High-Tech Enterprise Certification

On October 12, 2023, the Shanghai Municipal Science and Technology Commission issued the “Notice on Publicizing the Second Batch of Proposed High-Tech Enterprises for 2023 in Shanghai,” under which Shanghai Hycells Biotechnology Co., Ltd. was honorably selected. Following a three-month public announcement period, Hycells Biotechnology was officially recognized as a Shanghai High-Tech Enterprise and awarded the corresponding certificate.

2024-03-06

He Yousheng
< 1...121314...18 >